Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Part of paid clinical trials in Kansas City, Missouri.

Sponsor
Oregon Health and Science University
Study ID
NCT07600177
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Hypertrophic Cardiomyopathy (HCM)

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Aficamten — DRUG
    Patients will be switched from mavacamten to aficamten. Mavacamten will be stopped at enrollment, and aficamten started 2 weeks later.

Study Details

This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).

Key Dates

Start date
May 5, 2026
Status verified
May 2026
Primary completion
Dec 31, 2026
Completion
Mar 15, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CMI
    Switching from mavacamten on day 1 to aficamten starting at week 2.

Primary Outcome Measure

Safety Endpoints [ Time Frame: Up to 16 weeks ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
St. Luke's Hospital - Mid America Heart InstituteKansas CityMissouri64111
Michael Nassif, MD
[email protected]
816-932-3458
Michael Nassif, MD (PRINCIPAL_INVESTIGATOR)
Oregon Health & Science UniversityPortlandOregon97239
Ahmad Masri, MD
[email protected]
503-494-7551

Find similar trials in Kansas City, MO

By research site
St. Luke's Hospital - Mid America Heart Institute· Kansas City, MOOregon Health & Science University· Portland, OR

Related Studies